Advertisement

Bluebird bio, a Cambridge gene-therapy company, appointed its first scientific advisory board (SAB) members today, and said it would expand clinical trials in its lead compounds.

The SAB comes on the heels of announcements last week of a new chief medical officer, Alexandre P. LeBeaut, a pharmaceutical industry veteran, and a deal with the French Muscular Dystrophy Association worth up to $4.2 million for its LentiGlobin treatment for beta-thalassemia and sickle cell anemia.

SOURCE

Advertisement
Advertisement